Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies

Trial Profile

Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; XL 888 (Primary)
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Sep 2023 to 1 Jun 2023.
    • 05 Jul 2017 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2021.
    • 05 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top